John Edward Blair, MD
Interventional Cardiology · Seattle, WANPI 1023042744
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 86.1% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $14,462 and has fallen 96.0% since, to $575 in 2025.
Across 225 payments — averaging $182.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$35K
- Shockwave Medical, Inc$1K
- Medtronic$763
- Abiomed$613
- Inari Medical, Inc.$448
- Edwards Lifesciences$424
- plus $2K from 22 others
Across 13 payments — averaging $4671.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$35K
- Pfizer$26K
What the payments were for
- Consulting fees$15,27537%
- Speaking & faculty fees$7,00017%
- Travel & lodging$7,83219%
- Food & beverage$10,97427%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 142 | $35,373 |
| Shockwave Medical, Inc | 13 | $1,044 |
| Medtronic(2 entities) | 12 | $763 |
| Abiomed | 7 | $613 |
| Inari Medical, Inc. | 5 | $448 |
| Edwards Lifesciences | 4 | $424 |
| Boston Scientific | 5 | $332 |
| Cardiovascular Systems Inc. | 1 | $269 |
| Teleflex LLC | 2 | $195 |
| Ancora Heart, Inc. | 1 | $194 |
| W. L. Gore & Associates, Inc. | 1 | $193 |
| Biotronik Inc. | 2 | $190 |
| Cvrx, Inc. | 1 | $171 |
| Penumbra, Inc. | 1 | $143 |
| Acist Medical Systems, Inc. | 3 | $124 |
| Philips North America LLC | 1 | $99 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $95 |
| Endotronix, Inc. | 1 | $74 |
| Amgen | 4 | $73 |
| Cardiva Medical, Inc. | 4 | $59 |
| Heartflow, Inc. | 1 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Johnson & Johnson | 1 | $32 |
| AstraZeneca | 2 | $28 |
| Terumo Medical Corporation | 1 | $25 |
| Pfizer | 2 | $15 |
| ZOLL Circulation Inc | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dragonfly OCT$10,975
- XIENCE SIERRA$4,913
- COROFLOW$4,744
- PRESSUREWIRE$4,395
- DRAGONFLY OPSTAR$2,007
- Xience V coronary stent system$1,964
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$627
- OPTIS$463
- FIELDER$411
- Diamondback Coronary$391
- XIENCE V$319
- Impella$305
- MAZOR X SYSTEM$276
- Xience Sierra Coronary Stent System$255
- SAPIEN 3 Ultra RESILIA$241
- SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH THE SHOCKWAVE C2+ CORONARY$202
- AccuCinch$194
- CARDIOFORM Septal Occluder$193
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$183
- Barostim Neo System$171
How this compares
$41,081 in reported general payments places this provider in the 85th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 179 | $241,104 |
| EntrestoSacubitril/Valsartan | 96 | $139,799 |
| JardianceEmpagliflozin | 47 | $70,634 |
| FarxigaDapagliflozin Propanediol | 25 | $26,644 |
| XareltoRivaroxaban | 25 | $25,914 |
| BrilintaTicagrelor | 15 | $9,462 |
| Metoprolol Succinate | 242 | $3,824 |
| Rosuvastatin Calcium | 204 | $2,892 |
| Atorvastatin Calcium | 185 | $2,186 |
| Losartan Potassium | 110 | $1,315 |
| ClopidogrelClopidogrel Bisulfate | 78 | $1,305 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 52 | $1,296 |
| Carvedilol | 99 | $1,039 |
| Amlodipine Besylate | 92 | $813 |
| Lisinopril | 57 | $608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $241,104179 claims |
| NovartisEntresto | $14 | $139,79996 claims |
| AstraZenecaFarxiga, Brilinta | $28 | $36,10740 claims |
| Johnson & JohnsonXarelto | $32 | $25,91425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 125 interventional cardiology providers in Washington.
Other interventional cardiology in Seattle
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Danny DvirSeattle$374K
- James McCabeSeattle$289K
- Christopher BrownSeattle$266K
- Lorenzo AzzaliniSeattle$233K
- Sidakpal PanaichSeattle$214K
- Christine ChungSeattle$210K
- Sameer GafoorSeattle$80K
- Ravi HiraSeattle$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.